IBM Watson Health, MAP Health team-up to address incidence of Substance Abuse Relapse

MAP Health Management platform

MAP Health Management and IBM Watson Health have teamed-up to address the pervasive problem of relapse among Americans suffering from Substance Use Disorder. Under the deal, MAP will integrate Watson cognitive technologies into the MAP Recovery Network Platform to enhance the platform’s existing capabilities around patient risk models. In doing so, it will help behavioral health and substance abuse treatment providers that use the MAP platform better predict and prevent incidence of relapse nationwide.

“It’s time to leverage an advanced cognitive technology platform like IBM Watson to help make the right, evidence-based decisions to best treat those suffering from addiction. This could help patients manage their disease more effectively over the long term,” Jacob Levenson, CEO of MAP Health Management, said in a statement. “Bringing Watson into MAP’s ecosystem has the potential to improve countless lives and reduce substance abuse costs. MAP and IBM Watson hope to make a huge impact.”

Currently, MAP’s platform is used to streamline clinical processes, promote better patient engagement, enable proactive care and optimize clinical and financial outcomes for behavioral health including Substance Use Disorder and addiction treatment. Since 2011, more than 40,000 individuals in the United States have benefitted from MAP’s support, data and technology. MAP has engaged over 200 providers and other professionals to improve behavioral health and addiction treatment. Embedding Watson technologies into the MAP platform will allow it to unlock and more easily act upon insights from MAP patient data that were previously hidden and overlooked by traditional solutions.

For example, case notes from a treatment expert or care manager can often be omitted or lost as part of an increasingly automated treatment process because they are a form of unstructured data from which traditional tools cannot capture and extract value. With Watson functionalities on board, the MAP platform will be able to read such case notes, to potentially surface insights for a clinician to consider when interacting with a patient.

Among the first companies to deploy the Watson-powered MAP offering is Aetna Behavioral Health which is already working with MAP to collect and analyze patient data in order to more sufficiently develop treatment protocol and long-term strategies to support a patient’s ability to achieve and remain in recovery.

“IBM Watson Health and MAP have the potential to positively impact the tens of millions of people and families suffering from addiction in the United States,” Kathy McGroddy-Goetz, VP of Partnerships and Solutions at IBM Watson Health, said in a statement. “MAP Health Management is widely recognized as having a robust addiction outcomes database. IBM’s Watson cognitive computing technology is a natural fit to further empower what MAP is doing to help improve qualitative and quantitative outcomes in the behavioral health and addiction treatment fields.”

It is estimated that addiction and substance abuse claim more than 125,000 lives per year in the United States, resulting in economic costs of up to 700 billion annually.